Musculoskeletal toxicity is a significant source of morbidity, noncompliance, and treatment discontinuation in patients taking adjuvant aromatase inhibitor (AI) therapy for estrogen receptor (ER) positive breast cancer, which can ultimately impact survival outcomes1. The gene discussed is CYP19A1; the disease is breast cancer.